Background-The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial assigned patients with type 2 diabetes mellitus to prompt coronary revascularization plus intensive medical therapy versus intensive medical therapy alone and reported no significant difference in mortality. Among patients selected for coronary artery bypass graft surgery, prompt coronary revascularization was associated with a significant reduction in death/myocardial infarction/stroke compared with intensive medical therapy. We hypothesized that clinical and angiographic risk stratification would affect the effectiveness of the treatments overall and within revascularization strata. Methods and Results-An angiographic risk score was developed from variables assessed at randomization; independent prognostic factors were myocardial jeopardy index, total number of coronary lesions, prior coronary revascularization, and left ventricular ejection fraction. The Framingham Risk Score for patients with coronary disease was used to summarize clinical risk. Cardiovascular event rates were compared by assigned treatment within high-risk and low-risk subgroups. Overall, no outcome differences between the intensive medical therapy and prompt coronary revascularization groups were seen in any risk stratum. The 5-year risk of death/myocardial infarction/stroke was 36.8% for intensive medical therapy compared with 24.8% for prompt coronary revascularization among the 381 coronary artery bypass graft surgery-selected patients in the highest angiographic risk tertile (Pϭ0.005); this treatment effect was amplified in patients with both high angiographic and high Framingham risk (47.3% intensive medical therapy versus 27.1% prompt coronary revascularization; Pϭ0.010; hazard ratioϭ2.10; Pϭ0.009). Treatment group differences were not significant in other clinical-angiographic risk groups within the coronary artery bypass graft surgery stratum, or in any subgroups within the percutaneous coronary intervention stratum. Conclusion-Among patients with diabetes mellitus and stable ischemic heart disease, a strategy of prompt coronary artery bypass graft surgery significantly reduces the rate of death/myocardial infarction MI/stroke in those with extensive coronary artery disease or impaired left ventricular function. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00006305.
T he Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial compared a strategy of prompt coronary revascularization added to intensive medical therapy (REV) and intensive medical therapy alone with deferred revascularization when clinically indicated (MED) in patients with type 2 diabetes mellitus and stable coronary disease. The survival rates were similar for both treatment strategies over an average 5.3 years of follow-up. 1, 2 The intended revascu-larization procedure, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), was selected before patients were randomized on the basis of the individual physician's preference, resulting in 2 strata of patients (MED versus PCI and MED versus CABG). [3] [4] [5] No treatment differences were observed in the rate of all-cause death or myocardial infarction (MI) in the MED versus PCI stratum in BARI 2D 1,2 or in Clinical Outcomes Utilization Revascularization and Aggressive Drug Evaluation (COUR-AGE). 6, 7 However, in the BARI 2D MED versus CABG stratum, significant reductions in the principal secondary end point of death/MI/stroke and the end point of cardiac death/MI were observed with CABG, mainly as a result of a significant reduction in the rate of MI. The explanations for this apparent benefit are multifactorial and have not been well defined.
Clinical Perspective on p 2124
Patients selected for the CABG stratum had more extensive coronary disease and worse angiographic characteristics than patients selected for PCI and were more likely to have an adverse outcome. In this setting, CABG may provide a complete and durable revascularization and may be more cardioprotective than medical therapy against future events. 1, 4 We sought to develop a risk score incorporating angiographic and related variables collected at the time of randomization that would be associated with the risk of major cardiovascular outcomes. We hypothesized that the relative benefit observed with CABG compared with initial medical therapy in reducing the composite end point of death/MI/stroke would be confined to patients at higher angiographic risk. Because long-term prognosis is also influenced by patient characteristics that may accelerate the atherosclerotic process, a second aim was to assess whether high clinical risk would augment the effectiveness of revascularization relative to medical therapy in terms of long-term cardiovascular outcomes.
Methods

Study Population and Treatment Strategies
A detailed description of the BARI 2D study design, protocol, patient characteristics, and consort diagram has been published previously. 8, 9 Briefly, BARI 2D is a multicenter, international, randomized, clinical trial comparing 2 major strategies in a 2ϫ2 factorial design in patients with type 2 diabetes mellitus and stable coronary artery disease: (1) prompt coronary revascularization (REV) versus deferred revascularization to be used only if clinically necessary (MED) and (2) glycemic control strategy of insulin sensitization versus insulin provision therapy to a target hemoglobin A 1c of Ͻ7.0%. The choice of revascularization (PCI or CABG) was determined after coronary angiography by the treating physician, and randomization was then stratified by the type of intended revascularization procedure. Patients selected for CABG generally had more extensive disease, total occlusions, and proximal left coronary disease and a greater myocardial jeopardy score than those selected for PCI. 4 After randomization, all patients were treated according to current guidelines for lipid and blood pressure management, smoking cessation, physical activity, and weight loss. 10 Medication use and achievement of risk factor-targeted therapeutic goals were measured at prespecified intervals during follow-up, and treatment was optimized. The protocol was approved by the institutional review board at the University of Pittsburgh and at each participating site. All patients provided written informed consent. The trial was supported by the National Institutes of Health with additional support from industry.
The trial enrolled 2368 patients between January 1, 2001, and March 31, 2005. 1 Eligible patients had type 2 diabetes mellitus and evidence of myocardial ischemia by either angiographically defined coronary artery disease with at least 1 coronary lesion Ն50% stenosis and abnormal noninvasive stress test results or typical angina and at least 1 coronary lesion that had Ն70% stenosis. Patients were excluded if they required immediate revascularization; had revascularization within the prior 12 months; or had left main coronary disease, creatinine Ͼ2 mg/dL, glycated hemoglobin A 1c Ͼ13.0%, class III or IV heart failure, or significant hepatic dysfunction. Patients were seen in clinic on a monthly basis for the first 6 months and quarterly thereafter. As of November 30, 2008, the vital status was known for 2283 patients (96%). The mean follow-up interval was 5.3 years (range, 3.4 -7.8 years). The primary outcome measure for this analysis is the composite end point of death/MI/ stroke, and the secondary outcome measures of interest are all-cause death and the composite end point of cardiac death/MI. All acute coronary syndrome events were adjudicated at a core ECG/MI laboratory, and cause of death was adjudicated by an independent Mortality and Morbidity Classification Committee in both cases masked to treatment assignment. 2 To quantify the risk of major cardiovascular outcomes in the BARI 2D patients, we developed a risk score from baseline angiographic and related variables. We then assessed the 2 treatment strategies (MED versus REV) within the PCI and CABG strata by different levels of angiographic risk. The Framingham score for recurrent coronary heart disease, as described by D'Agostino et al, 11 was used to further risk stratify the BARI 2D population at baseline. Outcome differences between MED and REV were assessed according to levels of clinical and angiographic risk.
Statistical Analysis
Baseline demographic, clinical, and angiographic characteristics were compared between patients selected for the PCI and CABG intended revascularization strata (Table 1) . Proportions, means and standard deviations, or medians and ranges are presented, and 2 statistics were used to compare categorical variables and Wilcoxon rank-sum tests for continuous variables.
The BARI 2D angiographic risk score was based on the predicted probability of experiencing a death, MI, or stroke by 3 years (By protocol, all patients should have had Ն3 years of follow-up).
Stepwise variable selection methods were used to create a logistic regression model, and the following candidate variables were considered: myocardial jeopardy index, number of diseased vessels with Ն50% stenosis (categorical variables for 2 and 3 diseased vessels), location of diseased vessels (right coronary, left circumflex, or left anterior descending artery), proximal left anterior descending artery disease Ն50%, presence of 1 or more proximal lesions Ն50%, total number of lesions Ն20%, history of prior coronary revascularization, left ventricular ejection fraction Ͻ50%, presence of total occlusions, and presence of class C lesions. The myocardial jeopardy index is defined as the number of myocardial territories supplied by significantly diseased main coronary arteries or their branches divided by the total number of myocardial territories. The Framingham score for recurrent coronary heart disease includes sex, age, history of diabetes mellitus (which is present in all BARI 2D patients), total cholesterol/ high-density lipoprotein, and the additional variables of systolic blood pressure and current smoking in women. 11 The angiographic risk score and the Framingham clinical risk score were calculated for each BARI 2D patient based on the individual's characteristics at study entry. The top tertile of patients based on the angiographic score were considered high angiographic risk, and the top tertile of patients based on the Framingham score were considered high clinical risk. For each score, the bottom 2 tertiles were labeled low risk.
Kaplan-Meier-estimated cumulative event rates and hazard ratios (HRs) with 95% confidence intervals from Cox proportional hazards regression models were used to compare the risk of cardiovascular events between the randomized treatment strategies within sub- *Probability of death, MI, or stroke by 3 years; "high" angiographic risk defined as Ն17.1% probability of death/MI/stroke event.
†Probability of subsequent cardiovascular disease event by 3 years; "high" Framingham risk defined as Ն17.5% probability of a cardiovascular disease event.
groups defined by individual angiographic factors and by the risk scores according to randomization stratum. 12, 13 In these analyses, time 0 was defined as the date of randomization; event times for composite outcomes were defined as the time to the first event, and if no event occurred, patients were censored at their last valid follow-up. The average follow-up was 5.3 years for death and 4.6 years for other cardiovascular event outcomes. Five-year KaplanMeier estimated events rates are presented because this time interval was used for the primary BARI 2D trial treatment comparisons. Cox regression models including randomized treatment, the subgroup variable, and the interaction term between treatment and the subgroup variable were created to evaluate the significance of the risk-treatment interaction. To account for the multiple comparisons conducted in this investigational analysis, a value of PϽ0.05 was considered marginally significant, a value of PϽ0.01 was considered statistically significant, and a value of PϽ0.001 was considered highly statistically significant.
Results
Of the 2368 patients enrolled in the BARI 2D trial, 763 (32.3%) were intended for CABG if randomized to revascularization. Compared with patients selected for PCI, those intended for CABG had a higher average myocardial jeopardy score and number of lesions; more frequently had 3-vessel disease and proximal left anterior descending artery disease; and were more often elderly, male, and white (Table   1) . A higher proportion of the PCI group had a history of prior revascularization, and left ventricular function was similar. Notable geographic differences were observed in the revascularization choice between PCI and CABG.
The HRs by treatment assignment (MED versus REV) according to individual angiographic factors are illustrated in Figure 1 for the end point of death/MI/stroke in the PCI and CABG strata. Among patients selected for PCI, there were no significant outcome differences between MED and REV in the overall group or within any of the individual angiographic subgroups. In contrast, among patients selected for CABG, a significant benefit of prompt revascularization was observed in patients with 3-vessel disease (Pϭ0.0084) and in patients with a high myocardial jeopardy score (Pϭ0.0038). The interaction between treatment assignment and subgroup level was not statistically significant for any of the designated angiographic subgroup variables.
Risk Models
Angiographic risk variables identified as independent predictors of death/MI/stroke in the BARI 2D population included myocardial jeopardy index, total number of lesions Ն20%, history of prior coronary revascularization, and left ventric- ular ejection fraction Ͻ50%; the logistic regression risk model is shown in Table 2 . The same angiographic predictor variables were identified and similar coefficients were obtained when the analysis was restricted to patients assigned to medical therapy or when a Cox regression model for death/ MI/stroke based on all follow-up data was created. The probability risk functions for the angiographic and Framingham risk scores are described in the online-only Data Supplement. With the angiographic risk function, the predicted probability of death/MI/stroke at 3 years ranged from 6.1% to 56.9% among the BARI 2D participants, and with the Framingham score, the 3-year risk of a coronary event ranged from 3.4% to 42.5%. One third of the patients had an angiographic score of Ն17.1% and were therefore classified as high angiographic risk ( Figure I in the online-only Data Supplement), and one third of the patients had a Framingham score of Ն17.5% and were thus classified as high clinical risk. Of note, the majority of patients (55%) classified in the high-risk angiographic group had 3-vessel disease and 42% had abnormal left ventricular ejection fraction, whereas the majority of patients (51%) classified in the low-risk angiographic group had single-vessel disease and only 6% had abnormal left ventricular ejection fraction. Several patient scenarios are presented in the online-only Data Supplement.
A high Framingham risk score and a high angiographic risk score were associated with a significantly increased risk of all-cause death and death/MI/stroke at 5 years in the BARI 2D population (Figure 2 ). In total, the trial was unable to contact 3.6% of the BARI 2D patients at the final vital status sweep in November 2008; the rate of missing data did not differ significantly by treatment assignment, angiographic risk strata, or Framingham risk strata.
The mean angiographic score was significantly higher among patients selected for CABG compared with those selected for PCI (18.1 versus 14.3; PϽ0.0001; Table 1 ). Patients with high angiographic risk scores accounted for 49.9% of the CABG stratum compared with 24.8% of the PCI stratum (PϽ0.0001), and a larger proportion of patients in the CABG stratum were categorized as clinically high risk by the Framingham risk score (Table 1) .
Treatment Comparisons by Risk Group
Angiographic Risk Group Comparisons
No significant treatment benefit was observed in the 382 low-risk CABG patients or in the 398 high-risk and 1204 low-risk PCI patients ( Figure 3A-3C) . However, among the 381 CABG stratum patients with high-risk angiographic characteristics, the risk of death/MI/stroke over 5 years of follow-up was significantly higher for those assigned to MED compared with REV (36.8% versus 24.8%; Pϭ0.005; Figure  3D ). A breakdown of the spontaneous and periprocedural status of the first MI and stroke event per patient is shown in Table I in the online-only Data Supplement. Similar patterns were noted for the composite end point of cardiac death/MI and MI alone (Figures III and IV in the online-only Data Supplement), whereas all-cause mortality and stroke outcomes were comparable between the MED and REV treatment groups within each angiographic risk and revascularization stratum (Figures II and V in the online-only Data Supplement).
Framingham and Angiographic Risk Group Comparisons
The 5-year risk of death/MI/stroke was 47.3% for MED compared with 27.1% for REV in the 211 CABG stratum patients with high Framingham and angiographic risk scores (Pϭ0.010) (Figure 4 and Table II in the online-only Data Supplement). The risks for cardiac death/MI in the MED and REV groups within this high risk CABG cohort were 37.9% and 17.4%, respectively (Pϭ0.011; Table II in the onlineonly Data Supplement). Treatment differences were not statistically or clinically significant in the other clinical risk-angiographic risk groups in the CABG stratum or in any of the PCI subgroup comparisons.
Based on Cox regression analysis, the HRs for MED versus REV for death/MI/stroke and cardiac death/MI were statistically significant in the patients classified as high risk by the angiographic score in the CABG stratum (HR for death/MI/ strokeϭ1.72, Pϭ0.0049; HR for cardiac death/MIϭ1.94, Pϭ0.0038; Figure 4) but not in the larger low-angiographicrisk group in the CABG stratum. Further stratification by Framingham risk score revealed that the treatment HR was significant only among patients who were high risk according to both the angiographic and clinical scales (HR for death/ MI/strokeϭ2.10, Pϭ0.009; HR for cardiac death/MIϭ2.41, Pϭ0.012; HR for MIϭ3.76, Pϭ0.0022; Table 3 and Figure  4 ). There were consistent patterns indicating that revascularization was relatively more advantageous among higher-risk patients; however, the interactions testing for modification of treatment effect by risk group were not statistically significant when risk was defined by angiographic, clinical, or both risk scores. Notably, in the CABG stratum, the treatment effect of MED versus REV did not differ significantly between the 2 angiographic risk groups for the end point of death/MI/stroke (interaction Pϭ0.26; Figure 4 ) or for cardiac death/MI (Pϭ0.082).
Discussion
The main finding of this report is that the treatment differences observed in the CABG stratum of the BARI 2D trial are confined to the subgroup of patients considered to be at high risk on the basis of their angiographic profile. In this group of patients, the benefit of revascularization is amplified in those patients considered to be at high clinical risk. Thus, for patients with type 2 diabetes mellitus who are suitable candidates for CABG with a greater atherosclerotic risk factor profile and more extensive coronary disease as defined by the angiographic risk score, prompt CABG is a reasonable treatment strategy compared with medical therapy alone to significantly reduce cardiovascular events, particularly spontaneous MI, over a 5-year period. The incidence of first spontaneous MI during follow-up among high-angiographic-risk patients was 21.1% in the medical therapy group compared with 6.5% in the CABG group without an increased risk of stroke (3.3% for MED versus 2.0% for REV; Table II in the online-only Data Supplement). In high-angiographic-risk patients with more diffuse disease, CABG provides conduits that bypass obstructive and nonobstructive atherosclerotic plaques, possibly offering a cardioprotective effect against future spontaneous plaque rupture. We did not observe a treatment difference between REV and MED for death/MI/stroke over Figure 3 . Death, myocardial infarction (MI), or stroke by angiographic risk score category and intended revascularization stratum. Each panel shows the Kaplan-Meier event rates for the composite outcome death/MI/stroke for patients randomized to medical therapy (MED; blue) and prompt revascularization (red) with the log-rank P value. Patients are stratified according to intended revascularization stratum and angiographic risk score. A, Percutaneous coronary intervention (PCI) stratum, low angiographic risk. B, PCI stratum, high angiographic risk. C, Coronary artery bypass graft surgery (CABG) stratum, low angiographic risk. D, CABG stratum, high angiographic risk.
5 years of follow-up in the angiographically defined high-risk patients in the PCI stratum, even in those with a high Framingham risk score. One potential explanation for this finding is that the high-risk PCI patients in BARI 2D had less severe coronary disease than the high-risk CABG patients.
The angiographic score we developed included myocardial jeopardy index, total number of lesions with Ն20% diameter stenosis, prior coronary revascularization, and left ventricular ejection fraction Ͻ50% as independent predictors of death/ MI/stroke. All baseline coronary angiograms were read at the Stanford angiographic core laboratory. The myocardial jeopardy index integrates the number of myocardial segments supplied by significantly diseased main coronary arteries or their branches. Thus, the myocardial jeopardy index is higher for patients with a greater number of diseased vessels, particularly vessels with proximal disease.
We used the Framingham Risk Score to assign a clinical risk level to individual patients in BARI 2D. The Framingham investigators have developed models for individuals with a history of coronary heart disease or ischemic stroke from the combined experience of the original Framingham cohort and participating offspring and their spouses. 11 Our data confirm that the Framingham model for patients with coronary disease can classify patients with established coronary artery disease and type 2 diabetes mellitus into higherand lower-risk groups. The Framingham score incorporates well-known atherosclerotic risk factors associated with more frequent coronary artery disease progression into a single score. It is possible that other scoring methods that cluster other or additional risk factor groupings may produce different results. 14, 15 To assess the concept that high clinical risk magnifies treatment differences in the angiographic score risk, we examined the randomized treatment difference using the EuroSCORE. 15 The relationship between the benefit of CABG compared with initial intensive medical therapy and risk was no more pronounced with the use of the EuroSCORE strata than with the BARI 2D angiographic score (see the online-only Data Supplement). Our report focuses on clinical event outcomes, including all-cause death, death/MI/stroke, all-cause death, and cardiac death/MI. CABG and PCI have been shown to reduce the likelihood of new or worsening angina 16 in this group of patients with type 2 diabetes mellitus and stable coronary disease. Risk stratification based on angiographic and Framingham scores may not have the same impact on treatment effect estimates for functional outcomes.
Although the results observed in this study support the concept that the benefit of revascularization with CABG is greater for high-risk patients, the interaction tests between the angiographic risk score, the Framingham risk score, and prompt revascularization were not statistically significant. The BARI 2D trial was designed to have sufficient power to detect differences between REV and MED in the entire trial population. Moreover, a statistically significant interaction was detected between treatment assignment and intended revascularization stratum, indicating that prompt revascularization resulted in lower death/MI/stroke rates in the CABG stratum but not in the PCI stratum (P for interactionϭ0.01). The BARI 2D trial, however, has limited power to test an interaction between risk scores and treatment assignment within 1 stratum of the trial. Thus, our finding that prompt revascularization with CABG is significantly beneficial in the subgroup of high-risk patients but not the subgroup of low-risk patients is suggestive but not definitive. Our results are consistent with other revascularization trials [17] [18] [19] in which CABG was beneficial compared with medical therapy alone for patients with reduced left ventricular function and extensive coronary artery disease, whether coronary artery disease was measured by number of diseased vessels, myocardial jeopardy, or number of lesions.
Limitations
In addition to the power limitations resulting from the fixed sample size of the BARI 2D trial, our angiographic risk score has not been validated in other patient populations. It remains to be seen whether these results can be replicated in other stable ischemic heart disease patient populations with or without type 2 diabetes mellitus.
It is also important to consider the implications of invasive interventions among those with lower risk scores. A trend favoring intensive medical therapy among those identified as candidates for PCI is evident in both the group with low Framingham risk score and the group with low angiographic risk score. We did not routinely use other methods such as fractional flow reserve to risk stratify our patients with borderline lesions (ie, luminal narrowing of 50%-70%). 20, 21 The BARI 2D entry criteria required that patients have myocardial ischemia as evidenced by Ն50% luminal narrowing in a major coronary vessel with abnormal noninvasive testing or by typical angina with Ն70% luminal narrowing. Perhaps some patients with less severe anatomic disease (50%-70% narrowings) and less severe ischemia on noninvasive testing in whom a coronary revascularization procedure would not be expected to show benefit were entered in the trial. During the BARI 2D enrollment period and trial, bare metal stents were more commonly used (56%). However, the rates of bare metal and drug-eluting stent use were similar in the low-and high-angiographic-risk groups who received PCI as their initial procedure.
Other angiographic scoring methods such as the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score are useful in assigning levels of angiographic risk. 22, 23 The BARI 2D trial was initiated and the core angiographic analysis was completed before the SYNTAX score was developed. Therefore, we are unable to compare our angiographic score to the SYNTAX score at this time. Patients with left main coronary disease Ͼ50% were not enrolled in BARI 2D. However, the 2 scoring methodologies are internally consistent in providing angiographic risk profiles and demonstrate an increased rate of MI in patients with more diffuse extensive coronary disease. 24 
Conclusions
The BARI 2D trial provides a unique opportunity to study a treatment strategy of prompt revascularization with CABG compared with medical therapy alone in diabetic patients with documented coronary disease. A comprehensive program was used to provide intensive medical therapy to all participants regardless of whether coronary revascularization was performed. 1, 5, 10 Thus, our findings apply to patients in whom a strategy of aggressive atherosclerotic risk factor reduction is performed with the potential to prevent more rapid coronary and cerebrovascular ischemic events. Even in this setting of coordinated medical care, our results suggest that high-risk patients with type 2 diabetes mellitus and more extensive coronary disease might benefit from prompt coronary revascularization with CABG compared with a strategy of "watchful waiting" to avoid subsequent MI and its longterm consequences.
